Upload
others
View
1
Download
0
Embed Size (px)
Citation preview
TRANSFORMING THE FUTURE
NASDAQ : TINY
FIRST. TRANSFORMATIVE. PROVEN.
SAFE HARBOR STATEMENT
This presentation may contain statements of a forward-looking nature relating to future events. Statements contained in this presentation that are forward-looking statements are intended to be made pursuant to the Safe Harbor Provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are subject to the inherent uncertainties in predicting future results and conditions. These statements reflect the Company’s current beliefs, and a number of important factors could cause actual results to differ materially from those expressed herein.
Please see the Company’s Annual Report on Form 10-K, as well as subsequent filings, filed with the Securities and Exchange Commission for a more detailed discussion of the risks and uncertainties associated with the Company’s business, including but not limited to the risks and uncertainties associated with venture capital investing and other significant factors that could affect the Company’s actual results. Except as otherwise required by Federal securities laws, Harris & Harris Group, Inc. undertakes no obligation to update or revise these forward-looking statements to reflect new events or uncertainties.
2
HARRIS & HARRIS GROUP
• NASDAQ: TINY
• NAV/Share: $3.51(1)
3
(1) NAV/Share as of December 31, 2014
CORPORATE MISSION
Harris & Harris Group Builds Transformative Companies
from Disruptive Science
4
COMPANY HIGHLIGHTS
• 30-Year History Building Companies
• Holds Equity in Over 20 Transformational Companies
• Value Not Yet Realized
• Focused Strategy for Accelerated Growth
• Strong Interdisciplinary Team
• Ample Resources to Execute Successfully
5
Invest
Build ValueReturn
BUSINESS MODEL
Evergreen Structure Facilitates Growth
• NAV Growth• Company Building• Board Participation• Partnerships
• Early Stage• BIOLOGY+
6
Liq
uid
Early-Stage,Active Involvement
Late-StagePassive Involvement
Illiq
uid
Investing in Disruptive Science
OUR COMPETITIVE POSITION
7
Public VC Firms
Public Holding Companies
Private VC Firms
OUR COMPETITIVE POSITION
8
Health Care Technology
BioTherapeutics&
Medical Devices
Health Care Services
Physics
Materials Science
Data & Analytics
Mathematics
Electronics
Engineering
Chemistry
WHY EARLY-STAGE
9
• Opportunity to Generate Outsized Returns
• Addressing Unmet Needs of S&P 500 Corporations
• Limited Competition
• Ability to Influence Company Strategy & Execution
Unique Skillset for Investing in BIOLOGY+
RECOGNIZED LEADERSHIP IN EARLY-STAGE
10
#1 Venture Capital Investor in High-Technology
As measured by GrantIQ’s SBIR Source in February 2014: www.sbirsource.com/sbir/investors
WE HAVE EXPERIENCE BUILDING COMPANIES
(Amgen, 2011) (NASDAQ:SZYM, 2011)
(CordenPharma, 2013)
(Asahi Kasei, 2011)
(Carl Zeiss, 2013)
Xradia Ancora
BioVex Crystal ISSolazyme
11
(Canon, 2014)
Molecular Imprints
Examples of recent Biology+ exits
GAME PLAN FOR ACCELERATED GROWTH
12
• Realize Value in Current Portfolio• Invest in BIOLOGY+• Partner for Resources & Expertise• Return Value to Shareholders
Note: Equity-focused portfolio companies, year of first investment and stage classifications as of December 31, 2014, not including 1) our publicly traded shares of Solazyme; 2) our rights to milestone payments associated with the acquisitions of BioVex Group, Nextreme Thermal Solutions and Molecular Imprints; and 3) portfolio companies currently in the process of being liquidated, have ceased or are in the process of ceasing operations and/or are seeking a sale of their assets, including Laser Light Engines, Ultora, Synglyco and Cobalt.
PORTFOLIO BY STAGE
LATEEARLY MID
Mersana
Enumeral
ABS
Senova
AgBiome
EchoPixel
ProMuc
Nantero SiOnyx
OpGen
HZO
Bridgelux
Nanosys Cambrios
Adesto
PWA
Ensemble
Champions
D-Wave
Metabolon
BIOLOGY+
Other
Molecular Imprints
UberSeq
Accelerator
TARA Biosystems
METABOLON
• Leader in Metabolomics: 3,000+ Studies, 60+ Patents, $96+ Million Cumulative Revenue
• 2013 Released Three Diagnostic Tests Targeting Diabetes & Cancer
14
Actionable Diagnosis
• Initial Investment: 2006 • Capital Invested: $ 7.2 Million • Voting Ownership: 10-15%• Late Stage
Metabolomics Measure
Disease Status
DNA
RNA
Proteins
Disease/ Treatment
Mechanism
Biochemicals
Genetics Show Disease Risk
CHAMPIONS ONCOLOGY
• Validated & Differentiated Platform for Personalized Medicine
• Personalizing Treatments for Otherwise Untreatable Cancers
• Accelerating Development of New Therapies for Cancers
• $12M Rev. Run Rate, Growing at 50%
15
>80% Positive Predictive Value
• Initial Investment: 2011• Capital Invested: $1.6 Million • Ownership: ~2.5-5%• Late Stage
TumorGraftTMMouse
Predictive Treatments
D-WAVE
• Only Commercial Quantum Computer in the World
• Demonstrating 10,000-100,000x Faster Problem Solving
• Partnered with Lockheed, Google, and NASA
16
• Initial Investment: 2006• Capital Invested: $5.8 Million • Voting Ownership:
HZO
• Provides Submersion Protection for Electronic Devices
• Targeting Wearable, Defense, and Mobile Device Markets
• Customers Include Top Brands and Manufacturers in Wearables
17
Submersion Protection
• Initial Investment: 2011• Capital Invested: $8.4 Million • Voting Ownership: 15-20%• Mid Stage
Interdisciplinary innovation is required to address these healthcare challenges.
HEALTHCARE TECHNOLOGY
SOLUTIONSBIOLOGY
Electronics
Physics
Materials Science
Chemistry
IT
Engineering
Mathematics
DISTINCTIVE APPROACH
18
BIOLOGY ENABLES H&H PORTFOLIO COMPANY
Engineering Single Cell Analysis
Big DataCrop Protection
Solutions
Physics Predictive Physiology
ITProtein Structure
Analysis
MathematicsHigh-Quality
Molecular Diagnostics
Material ScienceTargeted
Bio-CompatibleDrug Delivery
A DECADE OF BIOLOGY INVESTMENTS
19
UNIVERSITY RELATIONSHIPS
20
Universities
Note: Includes a selection of the universities from which portfolio technology was licenses or founders established since 2002, which is when the first of the current Managing Directors joined the firm.
40+Portfolio
Companies
Washington University
Cornell
University of Wisconsin
University College London
Tufts
CalTech
University of British Columbia
RPI
Harvard
Arizona State University
University of Texas
University of Minnesota
ColumbiaMIT
Johns Hopkins University
College of Wooster
Oxford
UC Santa Barbara
University of Toronto
University ofMichigan
UC Berkeley
Stanford
Princeton
Duke
University of Illinois
Cold Spring Harbor Laboratory
Technology Platforms
CompanyBuilding
MarketAccess
Scale &Manufacturing
Corporate Partner
Corporate Partners are Highly Complementary
Technology Platforms
CompanyBuilding
MarketAccess
Scale
PARTNERING EARLY IS BENEFICIAL
21
PORTFOLIO PARTNERS
22
H&HPortfolio
Public Sector
Private Sector
Note: Includes corporate partnerships since 2002, which is when the first of the current Managing Directors joined the firm.
NIST
DOE
NSF
NIH
DARPA
ONR
SephoraCrucell
BOSCH
3M
Celgene
syngenta
MicrosoftHealth Diagnostic Laboratory, Inc.
LIFE Technologies
NASA
Bristol Myers Squibb
Bunge
Chevron
Coherent
Dow
Genentech
Hitachi Chemical
Illumina
Intel
LG Innotek
Lockheed MartinMetter Toledo
Mitsui
Panasonic
Samsung
Sanofi-Aventix
SynapticsUnilever Tyco
Novartis
Boehringer Ingelheim
Oxford Biosciences
Pfizer
Corporations currently add value to Harris & Harris Group and our portfolio companies in multiple ways.
CURRENT EXAMPLE OF OUR PARTNERING STRATEGY
23
RETURNING VALUE FOR SHAREHOLDERS
24
Generate Meaningful Returns by
Increasing Net Asset Value (NAV) per Share
GROWTH IN AVERAGE OWNERSHIP
Notes: Average ownership data includes investment-weighted ownership percentages on a fully diluted basis as of December 31, 2014, for unrealized investments including investments in pending tranches of previously closed financings, as applicable. Many of our current portfolio companies may raise additional capital, and depending on many factors our ownership could increase or decrease in these companies as a result of these financings. The data for 2005-2008 does not include ownership in Ancora Pharmaceuticals Inc. If this investment was included, the investment-weighted average ownership would be approximately 16 percent. There is no guarantee that the projections of average future ownership will be achieved. Do not place undue reliance on such projections.
5%
9%
15%
20%+
0%
5%
10%
15%
20%
2001-2004 2005-2008 2009-2014 Goal
Ave
rage
Ow
ner
ship
25
STRONG INTERDISCIPLINARY TEAM
26
Doug Jamison CEO, Managing Director
Daniel Wolfe, PhDPresident, COO, and Managing Director
• 90 Years of Experience* • 35 Exits for $2.5 Billion**• Domain Expertise
Alexei Andreev, PhDEVP, Managing Director
Misti Ushio, PhDCSO, Managing Director
Blake Stevens, PhDVP, Senior Associate
*Includes Investing and Industry experience** Total value of portfolio companies at time of exit without milestone
payments since 2002, when first deal team member joined
COMPANY HIGHLIGHTS
• 30-Year History Building Companies
• Holds Equity in Over 20 Transformational Companies
• Value Not Yet Realized
• Focused Strategy for Accelerated Growth
• Strong Interdisciplinary Team
• Ample Resources to Execute Successfully
27
CORPORATE MISSION
Harris & Harris Group Builds Transformative Companies
from Disruptive Science
28
29